Drug Profile
LEO 29102
Alternative Names: LEO-29102Latest Information Update: 31 Jul 2020
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Acetamides; Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atopic-dermatitis in Netherlands (Topical, Cream)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atopic-dermatitis(In volunteers) in United Kingdom (Topical, Cream)
- 29 Aug 2015 Phase-II development for Atopic dermatitis is ongoing in Canada, Finland and Germany